drugset / Trial / NCT04421469
Triprilimab(JS001) and Chemotherapy Combined With Local Treatment for Multiple Metastatic NPC
Phase 2
Unknown
39 enrolled
Fujian Cancer Hospital
Jiangxi Provincial Cancer Hospital · collabZhejiang Cancer Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is a randomized, phase II, prospective, multicenter clinical trial to evaluate the efficacy and tolerability of JS001 and chemotherapy combined with local treatment in patients with multiple metastatic nasopharyngeal carcinoma.
Timeline
- Start
- 2020-06-15
- Primary completion
- 2023-04-15
- Completion
- 2023-06-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Triprilimab | Monoclonal antibody | 240 mg | — |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | — |
| Background | Nedaplatin | Small molecule | 80 mg/m2 | — |
| Background | Nedaplatin | Small molecule | 100 mg/m2 | — |